Last updated on February 2018

Long-Term Outcomes With Abatacept In Biologic Treatment-Naive Rheumatoid Arthritis Patients In Japanese Clinical Practice Settings


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Rheumatoid Arthritis
  • Age: Between 20 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Patients with RA who meet the 2010 American College of Rheumatology / European League against Rheumatisms (ACR/EULAR) RA Classification Criteria
  • Patients with RA with a moderate disease activity (SDAI: > 11 and 26)
  • Biologic-naive patients with treatment history csDMARDs
  • Patients who meet the following criteria by hematological examination:
  • Peripheral white blood cell count: 4,000/mm3
  • Peripheral lymphocyte count: 1,000/mm3
  • Blood -D-glucan negative
  • Patients who understand the investigator's explanation of study procedures and have given voluntary written consent to participate in this study
  • Patients initiated with abatacept at per their physician's therapeutic decision

Exclusion Criteria:

  • Past history of hypersensitivity to the components of the abatacept preparation
  • Disease complications from a comorbidity
  • Active infectious disease
  • Been judged by the investigator or the co-investigator as being inappropriate

Other protocol defined inclusion/exclusion criteria could apply

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.